Next Article in Journal
Stromal CCL2 Signaling Promotes Mammary Tumor Fibrosis through Recruitment of Myeloid-Lineage Cells
Next Article in Special Issue
Emerging Cancer Epigenetic Mechanisms Regulated by All-Trans Retinoic Acid
Previous Article in Journal
Survival from Cervical Cancer Diagnosed Aged 20–29 Years by Age at First Invitation to Screening in England: Population-Based Study
Previous Article in Special Issue
Emerging Contribution of PancRNAs in Cancer

LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma

Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Av. de Fuente Nueva s/n, 18071 Granada, Spain
GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, Av. de la Ilustración 114, 18007 Granada, Spain
Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, University of Granada, Av. de la Investigación 11, 18007 Granada, Spain
Health Research Institute of Granada (ibs.Granada), Av. Fuerzas Armadas 2, 18014 Granada, Spain
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2020, 12(8), 2080;
Received: 13 July 2020 / Accepted: 24 July 2020 / Published: 28 July 2020
(This article belongs to the Collection Regulatory and Non-Coding RNAs in Cancer Epigenetic Mechanisms)
Long non-coding RNAs (lncRNAs) are a heterogeneous class of non-coding RNAs whose biological roles are still poorly understood. LncRNAs serve as gene expression regulators, frequently interacting with epigenetic factors to shape the outcomes of crucial biological processes, and playing roles in different pathologies including cancer. Over the last years, growing scientific evidence supports the key role of some lncRNAs in tumor development and proposes them as valuable biomarkers for the clinic. In this study, we aimed to characterize lncRNAs whose expression is altered in tumor samples from patients with lung adenocarcinoma (LUAD) compared to adjacent normal tissue samples. On an RT-qPCR survey of 90 cancer-related lncRNAs, we found one lncRNA, DLG2-AS1, which was consistently downregulated in 70 LUAD patients. To gain insight into its biological function, DLG2-AS1 was cloned and successfully re-expressed in LUAD cancer cell lines. We determined that DLG2-AS1 is not a cis-regulatory element of its overlapping gene DLG2, as their transcription levels were not correlated, nor did DLG2-AS1 restoration modify the expression of DLG2 protein. Furthermore, after generating a receiver operating curve (ROC) and calculating the area under curve (AUC), we found that DLG2-AS1 expression showed high sensitivity and specificity (AUC = 0.726) for the classification of LUAD and normal samples, determining its value as a potential lung cancer biomarker. View Full-Text
Keywords: adenocarcinoma of lung; biomarkers; tumor; RNA; long noncoding adenocarcinoma of lung; biomarkers; tumor; RNA; long noncoding
Show Figures

Figure 1

MDPI and ACS Style

Arenas, A.M.; Cuadros, M.; Andrades, A.; García, D.J.; Coira, I.F.; Rodríguez, M.I.; Baliñas-Gavira, C.; Peinado, P.; Álvarez-Pérez, J.C.; Medina, P.P. LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma. Cancers 2020, 12, 2080.

AMA Style

Arenas AM, Cuadros M, Andrades A, García DJ, Coira IF, Rodríguez MI, Baliñas-Gavira C, Peinado P, Álvarez-Pérez JC, Medina PP. LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma. Cancers. 2020; 12(8):2080.

Chicago/Turabian Style

Arenas, Alberto M., Marta Cuadros, Alvaro Andrades, Daniel J. García, Isabel F. Coira, María Isabel Rodríguez, Carlos Baliñas-Gavira, Paola Peinado, Juan Carlos Álvarez-Pérez, and Pedro P. Medina. 2020. "LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma" Cancers 12, no. 8: 2080.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop